SGHT
Sight Sciences, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
2.95
P/S
2.48
EV/EBITDA
-3.84
DCF Value
$1.18
FCF Yield
-15.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
86.2%
Operating Margin
-48.0%
Net Margin
-49.7%
ROE
-55.7%
ROA
-33.3%
ROIC
-35.4%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $20.4M | $-4.2M | $-0.08 |
| FY 2025 | $77.4M | $-38.4M | $-0.74 |
| Q3 2025 | $19.9M | $-8.2M | $-0.16 |
| Q2 2025 | $19.6M | $-11.9M | $-0.23 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
2.49
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.